Montelukast to placebo + Placebo to montelukast

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mild Persistent Asthma

Conditions

Mild Persistent Asthma

Trial Timeline

May 1, 2012 → Dec 1, 2015

NCT ID

NCT01581710

About Montelukast to placebo + Placebo to montelukast

Montelukast to placebo + Placebo to montelukast is a pre-clinical stage product being developed by Merck for Mild Persistent Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01581710. Target conditions include Mild Persistent Asthma.

What happened to similar drugs?

8 of 17 similar drugs in Mild Persistent Asthma were approved

Approved (8) Terminated (2) Active (8)

✅Aricept (donepezil hydrochloride) + placeboEisaiApproved

✅Donepezil HClEisaiApproved

✅ElagolixAbbVieApproved

✅Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcgAstraZenecaApproved

✅Aliskiren + Hydrochlorothiazide + AmlodipineNovartisApproved

✅Rivastigmine PatchNovartisApproved

✅ElidelBayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01581710	Pre-clinical	Completed	May 1, 2012	Dec 1, 2015	Mild Persistent Asthma

Competing Products

20 competing products in Mild Persistent Asthma

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	32
Ranirestat + Placebo	Eisai	Phase 2/3	38
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	43
Donepezil HCl	Eisai	Approved	43
Donanemab + Aducanumab	Eli Lilly	Phase 3	40
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	35
Elagolix	AbbVie	Approved	35
AZD1446 + Placebo	AstraZeneca	Phase 2	35
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	29
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	43
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	35
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	40
MK-8931	Merck	Phase 1	29
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	32
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	43
LCZ696 + Sildenafil	Novartis	Phase 2	35
QCZ484 + Placebo	Novartis	Phase 1	29
Rivastigmine Patch	Novartis	Approved	43
AFQ056	Novartis	Phase 1	29
Canakinumab	Novartis	Phase 2	27